PURPOSE: Bone scintigraphy (BS) lacks sensitivity for detecting very early skeletal metastases (SM) in prostate cancer (PC) and is often limited by poor specificity. Also scintigraphic flare of SM can occur following effective treatment and mislead an early response assessment. We hypothesised that a flare reaction might amplify the signal from subclinical SM, increasing the sensitivity of BS and that the phenomenon may be specific for metastases. METHODS: We conducted a prospective study to determine the frequency of the flare phenomenon in patients with metastatic PC starting hormone therapy and to explore its utility in patients with negative staging scans but considered at high risk of SM and in those with equivocal baseline BS abnormalities. Ninety-nine patients commencing first-line hormone therapy had repeat BS at 6 weeks to score a flare reaction. RESULTS: Of 22 patients with unequivocal SM on the baseline scan, a flare occurred in 9 (41%). Of 36 high-risk localised prostate cancer patients with normal BS pre-treatment, the scan became positive for metastases at 6 weeks in 4 (11%). Of 41 patients with pre-treatment scintigraphic abnormalities of uncertain aetiology, a flare occurred in 8 cases (20%). All eight were confirmed to have SM by follow-up and imaging. Of the 33 remaining patients without a flare, 2 developed SM at 14 months and the remainder did not develop SM in a median follow-up period of 36 months. CONCLUSION: The flare phenomenon following initial hormone therapy can be used to improve both sensitivity and specificity of BS in PC.
PURPOSE: Bone scintigraphy (BS) lacks sensitivity for detecting very early skeletal metastases (SM) in prostate cancer (PC) and is often limited by poor specificity. Also scintigraphic flare of SM can occur following effective treatment and mislead an early response assessment. We hypothesised that a flare reaction might amplify the signal from subclinical SM, increasing the sensitivity of BS and that the phenomenon may be specific for metastases. METHODS: We conducted a prospective study to determine the frequency of the flare phenomenon in patients with metastatic PC starting hormone therapy and to explore its utility in patients with negative staging scans but considered at high risk of SM and in those with equivocal baseline BS abnormalities. Ninety-nine patients commencing first-line hormone therapy had repeat BS at 6 weeks to score a flare reaction. RESULTS: Of 22 patients with unequivocal SM on the baseline scan, a flare occurred in 9 (41%). Of 36 high-risk localised prostate cancerpatients with normal BS pre-treatment, the scan became positive for metastases at 6 weeks in 4 (11%). Of 41 patients with pre-treatment scintigraphic abnormalities of uncertain aetiology, a flare occurred in 8 cases (20%). All eight were confirmed to have SM by follow-up and imaging. Of the 33 remaining patients without a flare, 2 developed SM at 14 months and the remainder did not develop SM in a median follow-up period of 36 months. CONCLUSION: The flare phenomenon following initial hormone therapy can be used to improve both sensitivity and specificity of BS in PC.
Authors: Michel Bolla; Laurence Collette; Léo Blank; Padraig Warde; Jean Bernard Dubois; René-Olivier Mirimanoff; Guy Storme; Jacques Bernier; Abraham Kuten; Cora Sternberg; Johan Mattelaer; José Lopez Torecilla; J Rafael Pfeffer; Carmel Lino Cutajar; Alfredo Zurlo; Marianne Pierart Journal: Lancet Date: 2002-07-13 Impact factor: 79.321
Authors: R Venkitaraman; G J R Cook; D P Dearnaley; C C Parker; V Khoo; R Eeles; R A Huddart; A Horwich; S A Sohaib Journal: J Med Imaging Radiat Oncol Date: 2009-06 Impact factor: 1.735
Authors: Anders Widmark; Olbjørn Klepp; Arne Solberg; Jan-Erik Damber; Anders Angelsen; Per Fransson; Jo-Asmund Lund; Ilker Tasdemir; Morten Hoyer; Fredrik Wiklund; Sophie D Fosså Journal: Lancet Date: 2008-12-16 Impact factor: 79.321
Authors: J A Schneider; C R Divgi; A M Scott; H A Macapinlac; A D Seidman; S J Goldsmith; S M Larson Journal: J Nucl Med Date: 1994-11 Impact factor: 10.057
Authors: R Venkitaraman; G J R Cook; D P Dearnaley; C C Parker; R A Huddart; V Khoo; R Eeles; A Horwich; S A Sohaib Journal: Clin Oncol (R Coll Radiol) Date: 2008-11-06 Impact factor: 4.126
Authors: Katherine A Zukotynski; John Valliant; François Bénard; Steven P Rowe; Chun K Kim; Martin G Pomper; Steve Y Cho Journal: Clin Nucl Med Date: 2018-03 Impact factor: 7.794
Authors: Hossein Jadvar; Bhushan Desai; Lingyun Ji; Peter S Conti; Tanya B Dorff; Susan G Groshen; Mitchell E Gross; Jacek K Pinski; David I Quinn Journal: Clin Nucl Med Date: 2012-07 Impact factor: 7.794
Authors: Jean-Christophe Brisset; Benjamin A Hoff; Thomas L Chenevert; Jon A Jacobson; Jennifer L Boes; Stefanie Galbán; Alnawaz Rehemtulla; Timothy D Johnson; Kenneth J Pienta; Craig J Galbán; Charles R Meyer; Timothy Schakel; Klaas Nicolay; Ajjai S Alva; Maha Hussain; Brian D Ross Journal: PLoS One Date: 2015-04-10 Impact factor: 3.240
Authors: Aseem Anand; Michael J Morris; Steven M Larson; David Minarik; Andreas Josefsson; John T Helgstrand; Peter S Oturai; Lars Edenbrandt; Martin Andreas Røder; Anders Bjartell Journal: EJNMMI Res Date: 2016-03-09 Impact factor: 3.138